RxDoctor Payments Data

Shelli Brown

Psychiatric/Mental Health · Atlantic, IANPI 1255058640

Payments from drug & device makers

$1,767in general payments, 2019–2025

Across 116 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$477
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377
  • Lundbeck LLC$250
  • Otsuka America Pharmaceutical, Inc.$174
  • Johnson & Johnson$126
  • Neurocrine Biosciences, Inc.$104
  • plus $260 from 6 others

What the payments were for

  • Food & beverage$1,71897%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,767 in reported general payments places this provider in the 65th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$26,851
Medicare patients
105
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil201$704,253
LybalviOlanzapine/Samidorphan Malate178$264,149
IngrezzaValbenazine Tosylate23$151,828
VraylarCariprazine Hcl92$145,662
CaplytaLumateperone Tosylate62$92,852
Invega TrinzaPaliperidone Palmitate11$92,718
RexultiBrexpiprazole59$88,472
Invega SustennaPaliperidone Palmitate21$58,863
TrintellixVortioxetine Hydrobromide70$34,804
LinzessLinaclotide40$21,846
Clozapine207$14,487
Vilazodone Hcl139$13,195
Clozapine OdtClozapine34$8,450
Aripiprazole210$6,111
Quetiapine Fumarate241$5,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada, Lybalvi$477$968,402379 claims
AbbVieVraylar, Linzess$56$167,508132 claims
Neurocrine Biosciences, Inc.Ingrezza$104$151,82823 claims
Johnson & JohnsonInvega Trinza, Invega Sustenna$126$151,58132 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$377$92,85262 claims
Otsuka America Pharmaceutical, Inc.Rexulti$174$88,47259 claims
Teva Pharmaceuticals USA, Inc.Loxapine$80$1,45431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Atlantic

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →